|
| (4-chloro-2-methyl-5-oxo-1-phenyl-2,5-dihydro-1H-pyrazol-3-yl)methyl imidothiocarbamate |
|
Helicobacter |
Flagella |
Preclinical (in vivo) |
Suerbaum S, et al. 2022. mBio |
|
| 3-(2,4-dichloroanilino)-N-hydroxypropanamide |
|
Helicobacter |
Urease |
Preclinical (in vivo) |
Liu Q, et al. 2018. Eur J Med Chem |
|
| 3-(2-chloroanilino)-N-hydroxypropanamide |
|
Helicobacter |
Urease |
Preclinical (in vivo) |
Liu Q, et al. 2018. Eur J Med Chem |
|
| 3-(3,5-dichloroanilino)-N-hydroxypropanamide |
|
Helicobacter |
Urease |
Preclinical (in vivo) |
Liu Q, et al. 2018. Eur J Med Chem |
|
| C14H11ClO |
|
Helicobacter |
Biofilm |
Preclinical (in vivo) |
Di Fermo P, et al. 2020. Antibiotics (Basel) |
|
| 4-[(E)-2-(4-methylphenyl)ethenyl]phenol |
|
Helicobacter |
Biofilm |
Preclinical (in vivo) |
Di Fermo P, et al. 2020. Antibiotics (Basel) |
|
| Resveratrol |
|
Aeromonas
Helicobacter
Staphylococcus |
Biofilm
Biofilm
α-hemolysin |
Preclinical (in vitro)
Preclinical (in vivo)
Preclinical (in vivo) |
Santos CA, et al. 2021. Front Microbiol
Di Fermo P, et al. 2020. Antibiotics (Basel)
Duan J, et al. 2018. Emerg Microbes Infect |
|
| Ap(S)A |
|
Mycobacterium |
Immune modulation |
Preclinical (in vivo) |
Dey RJ, et al. 2017. Nat Chem Biol |
|
| Ethoxzolamide |
|
Mycobacterium |
Regulation |
Preclinical (in vivo) |
Johnson BK, et al. 2015. Antimicrob Agents Chemother |
|
| Thioridazine |
|
Neisseria |
Type IV pili |
Preclinical (in vivo) |
Denis K, et al. 2019. Nat Microbiol |
|
| | | |
